Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

White matter disease

Optimizing rituximab therapy for neuromyelitis optica

Nature Reviews Neurology volume 7, pages 664–665 (2011)Cite this article

Subjects

Rituximab is an immunosuppressive monoclonal antibody therapy that is used in some cases to help prevent relapses of neuromyelitis optica, an inflammatory CNS demyelinating disease. A new study provides evidence supporting efficacy and a strategy for optimizing the timing of repeated courses of treatment for the individual patient.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J. & Weinshenker, B. G. The spectrum of neuromyelitis optica. Lancet Neurol. 6, 805–815 (2007).

    Article  CAS  Google Scholar 

  2. Lennon, V. A. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106–2112 (2004).

    Article  CAS  Google Scholar 

  3. Hinson, S. R. et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69, 2221–2231 (2007).

    Article  CAS  Google Scholar 

  4. Cree, B. A. et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64, 1270–1272 (2005).

    Article  CAS  Google Scholar 

  5. Jacob, A. et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neurol. 65, 1443–1448 (2008).

    Article  Google Scholar 

  6. Pellkofer, H. L. et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76, 1310–1315 (2011).

    Article  CAS  Google Scholar 

  7. Kim, S. H., Kim, W., Li, X. F., Jung, I. J. & Kim, H. J. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch. Neurol. http://dx.doi.org/10.1001/archneurol.2011.154.

  8. Palace, J. et al. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch. Neurol. 67, 1016–1017 (2010).

    Article  Google Scholar 

  9. Shimizu, J. et al. IFNβ-1b may severely exacerbate Japanese optic–spinal MS in neuromyelitis optica spectrum. Neurology 75, 1423–1427 (2010).

    Article  CAS  Google Scholar 

  10. Hinson, S. R. et al. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch. Neurol. 66, 1164–1167 (2009).

    Article  Google Scholar 

Download references

Acknowledgements

The authors receive research support from the Guthy–Jackson Charitable Foundation.

Author information

Authors and Affiliations

  1. Department of Neurology, Division of Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, 85255, AZ, USA

    Dean M. Wingerchuk

  2. Mayo Clinic, 200 First Street Southwest, Rochester, 55905, MN, USA

    Brian G. Weinshenker

Authors
  1. Dean M. Wingerchuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian G. Weinshenker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean M. Wingerchuk.

Ethics declarations

Competing interests

D. M. Wingerchuk has received research support from Alexion, Genentech and Genzyme. B. G. Weinshenker serves as a member of data safety monitoring committees for clinical trials sponsored by Biogen-Idec and Novartis. He receives royalties related to a patent for a test for neuromyelitis optica that has been licensed to a third party, RSR.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wingerchuk, D., Weinshenker, B. Optimizing rituximab therapy for neuromyelitis optica. Nat Rev Neurol 7, 664–665 (2011). https://doi.org/10.1038/nrneurol.2011.154

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2011.154

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing